Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crinetics Pharmaceuticals Inc
(NQ:
CRNX
)
42.12
-0.17 (-0.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
563,205
Open
42.49
Bid (Size)
40.74 (1)
Ask (Size)
43.42 (1)
Prev. Close
42.29
Today's Range
41.66 - 42.87
52wk Range
15.76 - 49.58
Shares Outstanding
54,026,103
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
March 19, 2024
Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy & safety, with plans for FDA submission in 2024.
Via
Benzinga
Exposures
Product Safety
Performance
YTD
+19.02%
+19.02%
1 Month
-5.20%
-5.20%
3 Month
+13.29%
+13.29%
6 Month
+48.73%
+48.73%
1 Year
+125.36%
+125.36%
More News
Read More
Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Leading the Way in Tuesday Trading Based on Percentage Gain
March 19, 2024
Via
Investor Brand Network
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
March 19, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 Experts
February 29, 2024
Via
Benzinga
Crinetics Pharmaceuticals: Q4 Earnings Insights
February 28, 2024
Via
Benzinga
Crinetics Pharmaceuticals Earnings Preview
February 27, 2024
Via
Benzinga
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 19, 2024
Via
Benzinga
Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win
March 19, 2024
Via
Investor's Business Daily
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
March 19, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Analyst Scoreboard: 4 Ratings For Crinetics Pharmaceuticals
December 19, 2023
Via
Benzinga
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
March 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 11, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 28, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
February 28, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
February 14, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
January 23, 2024
Via
Benzinga
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 28, 2023
Via
Benzinga
Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study
December 19, 2023
Via
Benzinga
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
December 18, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.